Key Developments For Harvard Bioscience Inc
Harvard Bioscience Inc (HBIO.O) (Consolidated Issue listed on NASDAQ Global Market)
Harvard Bioscience Issues Q4 2009 Guidance; Raises FY 2009 Guidance
Harvard Bioscience announced that with the acquisition of Denville, it is raising its guidance for the fiscal 2009 for revenues from $77.0 to $80.0 million to $83.0 to $84.0 million, and non-GAAP adjusted diluted earnings per share from $0.27 to $0.31 to non-GAAP adjusted diluted earnings per share of $0.28 to $0.31. In the fourth quarter 2009, the Company expects revenues in the $25.0 to $27.0 million range and non-GAAP adjusted earnings per share in the $0.08 to $0.11 range.
Harvard Bioscience Acquires Denville Scientific, Inc.
Harvard Bioscience announced that it has acquired the business of Denville Scientific, Inc. through a purchase of substantially all of Denville's assets and the assumption of certain of Denville's liabilities. Denville Scientific is a privately held distributor of molecular biology products. The purchase price is expected to be in the range of $23 million to $24 million. Harvard Bioscience expects to fund the acquisition from its existing cash balances and its credit facility.
Harvard Bioscience Lowers FY 2009 Revenue Outlook; Lowers High-End of Prior FY 2009 EPS Outlook Range; Issues Q3 2009 Outlook
Harvard Bioscience announced that for fiscal 2009, it has lowered revenue outlook to a range of $77.0 million to $80.0 million, and lowered high-end of prior non-GAAP adjusted diluted earnings per share (EPS) outlook to a range of $0.27 to $0.31. For the third quarter of 2009, it expects revenues in the $19.0 million to $20.0 million and non-GAAP adjusted earnings per share in the $0.06 to $0.07 range.
Harvard Bioscience Reaffirms FY 2009 Guidance; Issues Q2 2009 Guidance
Harvard Bioscience reconfirmed its guidance for fiscal 2009 of $80.0-$85.0 million in revenues and $0.27-$0.32 in non-GAAP adjusted earnings per share (EPS). In the second quarter of 2009, the Company sees revenues in the $18.5-$19.5 million range and non-GAAP adjusted EPS in the $0.05-$0.06 range.
Harvard Bioscience Issues Q1, FY 2009 Guidance
Harvard Bioscience announced that for fiscal 2009, without acquisitions it expects revenues to be in the $80.0-$85.0 million range and non-GAAP earnings per share (EPS) in the $0.27-$0.32 range. For the first quarter of 2009, without acquisitions the Company expects revenues to be in the $19.0-$20.0 million range and non-GAAP EPS in the $0.06-$0.07 range.
